If you grew up in docs, or know someone who did, the brand needs no introduction. What might surprise you is that Dr Martens (ticker DOCS.L) now trades as a London-listed investment — and right now it’s priced well below where analysts think it should be. That gap between current price and consensus target is exactly what this article is built to unpack.

4 related posts

Current Price: 67.20p – 68.00p · 52-Week Range: 51.05p – 100.87p · Market Cap: £707.0m · Consensus: Buy

Quick snapshot

1Confirmed facts
  • Current price range: 66–70p (Stockopedia financial data platform)
  • Dividend FY25 total: 2.55p (DividendMax UK dividend database)
  • Trailing yield: 3.65% (Stockopedia financial data platform)
2What’s unclear
  • Long-term recovery timeline for demand
  • Whether FY26 dividend matches FY25 total
  • Exact timing of analyst target achievement
3Timeline signal
  • FY25 final dividend paid October 2025
  • FY26 interim ex-date: 6 March 2026
  • 2 dividends typically paid per year
4What happens next
  • Analyst consensus target: 103.50p (Stockopedia financial data platform)
  • Payout ratio flagged at 368% for 2025 (Stockopedia)
  • Revenue declines continue to pressure outlook (Stockopedia)

Key trading and financial snapshot for DOCS.L as of recent sessions.

Label Value
Ticker DOCS.L
Exchange LSE
Previous Close 67.50p
Day Range 66.00p – 70.10p
Volume 525,827
52 Week Range 51.05p – 100.87p

Are Dr Martens shares a good buy?

Analyst ratings

The overall consensus recommendation for Dr Martens is Buy, according to aggregation data from Stockopedia (financial data platform). The analyst consensus target price sits at 103.50p, which represents 48.07% upside from the 69.90p closing price observed in recent trading. Fintel (stock analysis aggregator) places the average one-year price target at 102.15 GBX with a range spanning 76.76p to 148.05p. That 48% implied upside is the headline figure driving buy recommendations — but it comes with conditions attached.

The upshot

Analysts see nearly 50% upside from current levels, yet the stock has drifted lower for quarters. That gap is the investment thesis — and the risk.

Recent performance factors

Several performance factors weigh on the picture. Revenue in Europe, Middle East, and Africa has declined in recent quarters, dragging overall earnings. Simply Wall St (investment research platform) notes that dividend payments have decreased over the last decade, with payout ratios running at 165% — meaning dividends have been exceeding earnings. For 2025 specifically, Fidelity reports the payout ratio forecast at 368%, an extreme level that signals the dividend may not be sustainable at current levels without earnings recovery.

Why has Dr Martens’ share price dropped?

Revenue declines

Dr Martens has reported declining revenue amid what appears to be a broader demand normalisation following the post-pandemic boots frenzy. The brand built significant momentum during 2020–2022 as its chunky-soled shoes became fashion centrepieces on social media and among younger consumers. That surge has since unwound. The company faces a strategic shift as it attempts to move beyond hype-driven purchasing toward more durable brand relevance — a transition that typically pressures short-term revenue figures.

Regional demand issues

The EMEA (Europe, Middle East, Africa) region has been a particular pain point. Trading updates have pointed to softening consumer spending in core European markets, with the UK not immune. As Digrin (dividend tracker) documents, declining demand in this geography has contributed to reduced earnings guidance. The brand’s reliance on trend-driven purchases makes it vulnerable when fashion cycles shift — and right now, the cycle is not doing Dr Martens any favours.

What to watch

The 6 March 2026 ex-date for the 0.85p interim dividend signals the next cash event for shareholders — but demand stabilisation in EMEA matters more than dividend dates for long-term price recovery.

What is the stock price forecast for Doc Martens?

Analyst price targets

Looking across multiple sources, the picture is moderately constructive but not without scepticism. Stockopedia records the consensus target at 103.50p, representing 48.07% upside. Fintel’s data shows an average one-year target of 102.15 GBX with a range of 76.76p to 148.05p. The broad spread reflects genuine disagreement among analysts about whether Dr Martens can arrest its revenue slide.

2026 predictions

StockInvest (quantitative forecasting platform) places short-term forecasts in a 110.34p to 145.00p range over three months, implying a potential 48.51% rise. For longer horizons, Fintel shows a forecasted EPS of 0.06 per share by March 2029. The Investing.com dividend page puts current yield at 3.89% with a payout ratio of 115.69% and EPS at 0.01546. Forecast data from Fidelity (investment platform) shows a 2026 dividend forecast of 0.0085p per share — notably below the FY25 total of 2.55p.

Does Dr Martens pay a dividend?

Current yield

Yes — Dr Martens pays dividends twice yearly, typically, as documented by DividendMax (UK dividend database). The trailing dividend yield stands at 3.65%, while forward yield estimates from Simply Wall St sit at 3.9%. The 52-week high yield was 7.1% on 7 April 2025, and the 52-week low was 2.4% on 30 September 2025. Those swings reflect the interplay between the share price falling and the dividend payout remaining relatively sticky — at least for now.

Payment history

The dividend history tells a story of contraction. For FY25, the total dividend was 2.55p — 1.70p final paid 8 October 2025 and 0.85p interim with ex-date 6 March 2026. This matched the FY24 total of 2.55p exactly, which itself was a steep drop from FY23’s total of 5.84p paid 18 July 2023. Fidelity data confirms the FY24 total was 2.55p with a 35% payout ratio, and the FY23 total was 5.84p. The decline from 5.84p to 2.55p represents a more than 50% reduction in annual dividend income per share — a significant deterioration that the yield percentage partially masks because the share price has fallen in parallel.

Why this matters

Yield figures look attractive at current prices, but they’re based on a dividend that has been cut sharply and may face further reduction if earnings do not recover. A 3.9% yield on a collapsing payout is not the same proposition as a 3.9% yield on a stable business.

Is Dr. Martens in financial trouble?

Revenue trends

Dr Martens is not in acute financial distress — the company remains profitable and continues paying dividends. But the trajectory is concerning. Revenue declines have been persistent enough to trigger earnings downgrades. The payout ratio of 368% for 2025, per Fidelity data, means the company is paying out more in dividends than it earns — a situation that cannot continue indefinitely without either earnings recovery or a dividend cut. AJ Bell records the most recent ex-dividend at 5 March 2026 for 0.85p with payment on 9 April 2026.

Strategic responses

The company is attempting a strategic shift away from pure trend dependency toward more durable brand equity. This involves expanding product categories, improving direct-to-consumer channels, and reducing reliance on the fashion cycle. Whether these efforts succeed will determine whether the analyst price targets prove achievable or remain permanently out of reach. The Investing.com dividend page shows a payout ratio of 115.69% with EPS at 0.01546, reinforcing the picture of a business under earnings pressure.

Upsides

  • Analyst consensus target of 103.50p implies 48% upside from current levels
  • Dividend still being paid at 2.55p for FY25 despite earnings pressure
  • 52-week price range of 51.05p – 100.87p shows the stock has been lower recently
  • Market cap at £707m may undervalue brand if recovery succeeds
  • Trailing yield of 3.65% offers income while waiting

Downsides

  • Payout ratio at 368% — dividends exceed earnings, unsustainable without change
  • Revenue declines ongoing in key EMEA markets
  • Dividend cut from 5.84p (FY23) to 2.55p (FY25) — 56% reduction
  • FY26 dividend forecast of 0.0085p suggests further pressure
  • Demand driven by fashion cycles, not durable brand loyalty
  • Stock has traded as high as 100.87p in past 52 weeks — currently near low end

Dividend and price history

Period Event Amount / Price Source
FY23 Total dividend paid 5.84p DividendMax
FY24 Total dividend paid 2.55p Fidelity
FY25 Final dividend paid 1.70p (8 Oct 2025) DividendMax
FY25 Interim ex-date 0.85p (6 Mar 2026) AJ Bell
Past 52 weeks Price range 51.05p – 100.87p Stockopedia
Current Trading range 66.00p – 70.10p Stockopedia

Three dividend declarations, one declining trajectory: the FY23 total of 5.84p has been roughly halved to 2.55p by FY25, with FY26 forecasts pointing lower still.

Bottom line: Dr Martens shares sit near the bottom of their 52-week range while analysts project 48% upside — a classic value-or-trap scenario. Income investors get a 3.65% trailing yield, but that payout rests on a 368% payout ratio that cannot hold. Growth investors face declining revenues and a dividend cut trend that may not have bottomed. Only those who believe the strategic shift will reverse demand weakness should consider DOCS.L at current levels.

What analysts and the company say

The overall consensus recommendation for Dr Martens is Buy.

Stockopedia (stock analysis platform)

The Dr Martens Board has declared a final dividend of 1.70p, taking the total dividend for FY25 to 2.55p.

Dr Martens Board (company announcement via DividendMax)

Dividend payments have decreased over the last 10 years with a payout ratio of 165%.

Simply Wall St (investment research platform)

Bottom line: Dr Martens shares sit near the bottom of their 52-week range while analysts project 48% upside — a classic value-or-trap scenario. Income investors get a 3.65% trailing yield, but that payout rests on a 368% payout ratio that cannot hold. Growth investors face declining revenues and a dividend cut trend that may not have bottomed. Only those who believe the strategic shift will reverse demand weakness should consider DOCS.L at current levels.

Related reading: Premier Foods Share Price

Additional sources

wisesheets.io, morningstar.com

Don't miss these

Frequently asked questions

What is the current Dr Martens share price?

Dr Martens (DOCS.L) trades in a range of approximately 67.20p to 68.00p as of recent sessions, according to data from Stockopedia. The previous close was 67.50p with a day range of 66.00p to 70.10p.

What is DOCS ticker symbol?

The ticker is DOCS.L on the London Stock Exchange (LSE). Some platforms display it as DOCS or GBX:DOCS.

Has Dr Martens share price recovered recently?

The share price remains near the lower end of its 52-week range of 51.05p to 100.87p. It has not recovered to prior highs, and the declining revenue environment continues to weigh on the stock.

What factors affect Dr Martens stock?

Key drivers include EMEA demand trends, fashion cycle dynamics, the strategic shift toward direct-to-consumer channels, payout ratio sustainability, and broader consumer spending conditions in Europe.

Is Dr Martens dividend safe?

At a 368% payout ratio in 2025, the dividend is not covered by earnings — a condition that raises questions about sustainability. The company has already cut the total dividend from 5.84p (FY23) to 2.55p (FY25). Further reduction is possible if earnings do not recover.

What is Dr Martens market cap?

Approximately £707.0 million at current prices, based on figures from Digrin.

Where to buy Dr Martens shares?

DOCS.L is listed on the London Stock Exchange and can be purchased through any UK brokerage that provides LSE access, or international brokers that offer UK equity trading.